BioSpace News Archive

Lifespin GmbH, a start-up medical diagnostics company with offices in Regensburg and Boston, announced that it has launched Lifespin™ Amino Acid Profiler - its first commercial product for use in the regulated diagnostics field.

AlzeCure Pharma AlzeCure Pharma AB, a pharmaceutical company that develops candidate drugs for CNS diseases, focusing on Alzheimer’s disease and pain, announced that the European Patent Office has granted a patent covering the company’s candidate drug ACD856, which is developed against Alzheimer’s disease and other disorders with cognitive impairment.

Atom Bioscience, a clinical stage biotechnology company developing new treatments for metabolic and inflammatory diseases, such as gout, is calling for increased understanding of gout to help mark Gout Awareness Day, May 22, 2023.

Intellego Technologies and HAI Solutions are proud to announce a strategic partnership that is designed to improve the quality and safety of intravenous (IV) vascular access.

Oculis Holding AG, a global biopharmaceutical company purposefully driven to save sight and improve eye care, announced positive top line results from Stage 1 of its Phase 3 DIAMOND trial of OCS-01 eye drops in Diabetic Macular Edema.

Affimed N.V. announced that its 2023 Annual General Meeting of Shareholders will be held on June 21, 2023 at 14:00 CET at the NH Collection Amsterdam Barbizon Palace, Prins Hendrikkade 59-72, 1012 AD Amsterdam, the Netherlands.

Viatris Inc. today announced that as part of its ongoing board refreshment efforts, Leo Groothuis has been appointed as Viatris’ newest member of its board of directors.

TransCode Therapeutics, Inc. today announced that its Board of Directors approved a 1-for-20 reverse stock split, to be effective 4:05 p.m. Eastern Time today, May 22, 2023.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Public Health Institute (ISP) of Chile has granted marketing authorization for oral, once-daily ORLADEYO ® (berotralstat) for the prophylaxis of hereditary angioedema (HAE) attacks in patients 12 years of age or older.

Athira Pharma, Inc. today announced the appointment of Andrew Gengos as Chief Financial Officer and Chief Business Officer, effective immediately.